Pharmaceutical

Bladder cancer victim files lawsuit against Actos maker

An Illinois man is suing the makers of the type 2 diabetes drug Actos, claiming the drug caused him to develop bladder cancer. His lawsuit alleges that the drug company was fully aware that the medication had been linked to bladder cancer but hid the risks from the public.

The lawsuit was filed earlier this month in Madison County Circuit Court against Actos makers Takeda Pharmaceuticals America Inc., Takeda Pharmaceuticals North America Inc., Takeda Pharmaceutical Company Limited, and Eli Lilly and Company.

The plaintiff was prescribed Actos in 2007 for the long-term control of his high blood sugar. He says he took Actos as prescribed every day until September 2011. In June 2010, he was diagnosed with bladder cancer, but didn’t learn that the drug carried a risk for the disease until months later.

According to the complaint, in 2010 the Food and Drug Administration (FDA) found an increased risk of bladder cancer in patients. The manufacturers denied the claims. After further review, in June 2011 the FDA issued a safety announcement stating that studies showed long-term use of Actos increased the risk for bladder cancer. The warning was immediately added to the drug’s safety label.

It was too late for the plaintiff in the lawsuit, who had already been diagnosed with cancer. He is accusing Takeda and Eli Lilly of negligence, strict liability and negligent failure to warn for allegedly hiding information about the risks posed by Actos. The lawsuit also alleges that manufacturers knew the risks of Actos far outweighed its benefits yet continued to distribute the drug.The plaintiff is suing for damages, including pain and suffering, economic loss, and court costs.

ACTOS, ACTOplus met, ACTOplus met XR, and duetact are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

Source: Madison/St. Clair Record